1. Zhou, Xueya, Feliciano, Pamela, Shu, Chang, Shen, Yufeng, Chung, Wendy K. 2022. Integrating de novo and inherited variants in 42,607 autism cases identifies mutations in new moderate-risk genes. In Nature genetics, 54, 1305-1319. doi:10.1038/s41588-022-01148-2. https://pubmed.ncbi.nlm.nih.gov/35982159/
2. Aghabozorg Afjeh, Sara Sadat, Shams, Jamal, Hamednia, Safar, Omrani, Amin, Omrani, Mir Davood. 2022. Validating MARK2 Gene Polymorphism as a Predictor of Response to Lithium Treatment in Bipolar Patients. In Iranian biomedical journal, 26, 110-5. doi:10.52547/ibj.26.2.110. https://pubmed.ncbi.nlm.nih.gov/34953473/
3. Zeng, Yongji, Yin, Ling, Zhou, Jiuli, Chen, Yuanhong, Dong, Jixin. 2022. MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer. In Oncogene, 41, 3859-3875. doi:10.1038/s41388-022-02399-3. https://pubmed.ncbi.nlm.nih.gov/35780183/
4. Chen, Shuyuan, Zhang, Qin, Bai, Baoling, Li, Huili, Zhang, Ting. 2016. MARK2/Par1b Insufficiency Attenuates DVL Gene Transcription via Histone Deacetylation in Lumbosacral Spina Bifida. In Molecular neurobiology, 54, 6304-6316. doi:10.1007/s12035-016-0164-0. https://pubmed.ncbi.nlm.nih.gov/27714636/
5. Wei, Xianfu, Xu, Liang, Jeddo, Salim Fa, Li, Xin, Li, Jianmin. 2020. MARK2 enhances cisplatin resistance via PI3K/AKT/NF-κB signaling pathway in osteosarcoma cells. In American journal of translational research, 12, 1807-1823. doi:. https://pubmed.ncbi.nlm.nih.gov/32509178/